Search

Your search keyword '"Paradis, Valérie"' showing total 1,310 results

Search Constraints

Start Over You searched for: Author "Paradis, Valérie" Remove constraint Author: "Paradis, Valérie"
1,310 results on '"Paradis, Valérie"'

Search Results

1. Primary liver cancer classification from routine tumour biopsy using weakly supervised deep learning

4. An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

5. Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort

9. Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies

10. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes

11. Identification of liver transplant biopsy phenotypes associated with distinct liver biological markers and allograft survival

12. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma

15. Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)

16. Prospective Comparison of Attenuation Imaging and Controlled Attenuation Parameter for Liver Steatosis Diagnosis in Patients With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes

19. Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort

20. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

23. Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis

26. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

29. Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice

37. WED-245 Should specific cutoffs be used for diagnosing fibrotic MASH in patients with type 2 diabetes using FAST, MAST, MEFIB and FNI?

39. WED-239 Proteomics identifies a subpopulation of plasma extracellular vesicles able to improve non-invasive diagnosis of MASH in patients with type 2 diabetes: results of the RHU QUID-NASH study

40. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma

41. Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma

42. The triglycerides and glucose (TyG) index: A new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients

47. Characterization and Pharmacological Validation of a Preclinical Model of NASH in Göttingen Minipigs

48. Hepatocellular adenoma update: diagnosis, molecular classification, and clinical course.

49. Orexins mitigate obesity‐associated dysfunctions in mice.

Catalog

Books, media, physical & digital resources